Table 3 Comparisons Among the Meta-analysis Assessing Different Methods for Differentiating Benign and Malignant Gallbladder Lesions

Myung-Won and Seong Jong

Diffusion Weighted Imaging

8

Sensitivity, specificity, HSROC curve

Stata 10.0, R software 3.4.1

Sensitivity: 0.91 (95% CI: 0.91–0.91); specificity: 0.87 (95% CI: 0.87–0.87); HSROC curve: 0.95 (95% CI: 0.93–0.97).

Non-invasive, objective

Inefficient

Wang, et al.

CEUS

16

Sensitivity, specificity, PLR, NLR, DOR, HSROC curve

Stata 11.0, Review Manager 5.0

Sensitivity: 0.92 (95%CI: 0.90, 0.94); specificity: 0.91 (95%CI: 0.89, 0.93);

PLR: 10.01 (95%CI: 7.02, 14.29);

NLR: 0.10 (95%CI: 0.07, 0.14);

DOR: 123.02 (95%CI: 78.40, 193.03);

HSROC curve: 0.9689 (95%CI: 0.9376, 0.9879).

Cost, non-invasive, no-radiation-exposure

Subject

Cheng, et al.

CEUS

12

Sensitivity, specificity, PLR, NLR, DOR, SROC curve

Stata 12.0

Sensitivity: 0.81 (95%CI: 0.77, 0.84); specificity: 0.87 (95%CI: 0.85, 0.89);

PLR: 10.43 (95%CI: 4.57, 23.83);

NLR: 0.19 (95%CI: 0.11, 0.33);

DOR: 58.84 (95%CI: 32.39, 106.88);

SROC curve: 0.9371.

Liang, et al. (the present study)

CEUS; CH-EUS

21

Sensitivity, specificity, DOR, SROC curve

Stata 15.0

(CEUS)

Sensitivity: 0.81 (95% CI: 0.75–0.86); specificity: 0.92 (95% CI: 0.86–0.95);

DOR: 64 (95%CI: 32, 127);

SROC curve: 0.90 (95% CI: 0.87–0.92).

(CH-EUS)

Sensitivity: 0.92 (95% CI: 0.86–0.95); specificity: 0.89 (95% CI: 0.69–0.97);

DOR: 89 (95%CI: 22, 354);

SROC curve: 0.92 (95% CI: 0.90–0.94).

(CEUS)

Cost, non-invasive, no-radiation-exposure

(CH-EUS)

Cost, no-radiation-exposure, high-resolution

(CEUS)

Subject

(CH-EUS)

Subject, invasive, inconvenient